Gamifant for Primary Hemophagocytic Lymphohistiocytosis
Gamifant (emapalumab-lzsg, Sobi)
Indications: patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
Dosage: 1 mg/kg as an intravenous infusion over 1 hour twice per week; Administer dexamethasone concomitantly with GAMIFANT.
Contraindications:None
Related Content
